Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD3-activating CD19-bi-specific antibody A-319

A recombinant T-cell activating bispecific antibody directed against the B-cell-specific membrane protein CD19 and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, CD3-activating CD19 bi-specific antibody A-319 targets and binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the CD19 antigen expressed on malignant B cells. This activates and redirects CTLs, bringing CD19-expressing tumor cells and CTLs together, and results in a CTL-mediated immune response against CD19-expressing tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B cell to early plasma cell stages.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:recombinant anti-CD19/CD3 antibody A-319
Code name:A 319
A-319
A319
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search